With 0.17 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.14 million shares. During the session, the Software – Application company that operates in wider Technology sector, reached to the highest price of $42.61 whereas the lowest price it dropped to was $41.51. The 52-week range on DBD shows that it touched its highest point at $51.81 and its lowest point at $30.37 during that stretch. It currently has a 1-year price target of $72.33. Beta for the stock currently stands at 1.67.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of DBD was up-trending over the past week, with a rise of 3.48%, but this was down by -3.70% over a month. Three-month performance dropped to -2.60% while six-month performance fell -8.62%. The stock gained 26.28% in the past year, while it has lost -2.65% so far this year. A look at the trailing 12-month EPS for DBD yields -0.44 with Next year EPS estimates of 4.63. For the next quarter, that number is 0.40. This implies an EPS growth rate of 69.46% for this year and 20.36% for next year. EPS is expected to grow by 30.11% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 37.08%.
Float and Shares Shorts:
At present, 37.58 million DBD shares are outstanding with a float of 36.95 million shares on hand for trading. On 2025-03-31, short shares totaled 0.86 million, which was 229.0 higher than short shares on 1740700800. In addition to Mr. Octavio Marquez as the firm’s President, CEO & Director, Mr. Thomas S. Timko serves as its Executive VP & CFO.
Institutional Ownership:
Through their ownership of 1.06446 of DBD’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-12-31, DBD reported revenue of $988900000.0 and operating income of $42500000.0. The EBITDA in the recently reported quarter was $79100000.0 and diluted EPS was $nan.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for DBD since 1 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With DBD analysts setting a high price target of 80.0 and a low target of 60.0, the average target price over the next 12 months is 72.33333. Based on these targets, DBD could surge 90.93% to reach the target high and rise by 43.2% to reach the target low. Reaching the average price target will result in a growth of 72.63% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of $3.73547 being high and $3.70978 being low. For DBD, this leads to a yearly average estimate of $3.72.
